NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment.
NK cells
chemokine receptors
dendritic cells
immunotherapy
macrophages
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
09
2021
accepted:
22
11
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
15
2
2022
Statut:
epublish
Résumé
NK cells are innate lymphoid cells endowed with cytotoxic capacity that play key roles in the immune surveillance of tumors. Increasing evidence indicates that NK cell anti-tumor response is shaped by bidirectional interactions with myeloid cell subsets such as dendritic cells (DCs) and macrophages. DC-NK cell crosstalk in the tumor microenvironment (TME) strongly impacts on the overall NK cell anti-tumor response as DCs can affect NK cell survival and optimal activation while, in turn, NK cells can stimulate DCs survival, maturation and tumor infiltration through the release of soluble factors. Similarly, macrophages can either shape NK cell differentiation and function by expressing activating receptor ligands and/or cytokines, or they can contribute to the establishment of an immune-suppressive microenvironment through the expression and secretion of molecules that ultimately lead to NK cell inhibition. Consequently, the exploitation of NK cell interaction with DCs or macrophages in the tumor context may result in an improvement of efficacy of immunotherapeutic approaches.
Identifiants
pubmed: 34975880
doi: 10.3389/fimmu.2021.787116
pmc: PMC8718597
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
787116Informations de copyright
Copyright © 2021 Russo, Laffranchi, Tomaipitinca, Del Prete, Santoni, Sozzani and Bernardini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Cell Immunol. 2018 Aug;330:188-201
pubmed: 29482836
Immunity. 2020 Aug 18;53(2):335-352.e8
pubmed: 32610077
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Elife. 2014 Aug 22;3:e04177
pubmed: 25149452
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Science. 2015 Nov 20;350(6263):985-90
pubmed: 26494174
PLoS One. 2012;7(6):e39170
pubmed: 22723958
J Immunol. 2018 Feb 1;200(3):1008-1015
pubmed: 29282306
Cancer Immunol Res. 2019 Aug;7(8):1280-1292
pubmed: 31189644
Cell Mol Immunol. 2020 Jan;17(1):1-12
pubmed: 31611651
Front Immunol. 2013 Jan 04;3:403
pubmed: 23316194
J Mol Med (Berl). 2012 Jan;90(1):55-66
pubmed: 21870102
Immunity. 2002 Nov;17(5):537-47
pubmed: 12433361
Cell. 2020 Feb 20;180(4):749-763.e13
pubmed: 32059780
Front Immunol. 2021 Jan 29;11:621225
pubmed: 33584718
Biomaterials. 2017 Jul;134:166-179
pubmed: 28463694
Clin Cancer Res. 2013 Apr 1;19(7):1858-72
pubmed: 23444227
Clin Cancer Res. 2018 Apr 15;24(8):1891-1904
pubmed: 29363526
J Exp Med. 2002 Feb 4;195(3):327-33
pubmed: 11828007
Front Immunol. 2019 Jul 10;10:1569
pubmed: 31354722
Int J Cancer. 2009 Jul 15;125(2):367-73
pubmed: 19378341
Cell Mol Immunol. 2018 Apr;15(4):346-352
pubmed: 29563613
Front Oncol. 2018 Mar 12;8:49
pubmed: 29594035
Nature. 2001 Sep 13;413(6852):165-71
pubmed: 11557981
Cancer Cell. 2005 Nov;8(5):369-80
pubmed: 16286245
Nat Rev Immunol. 2006 Jul;6(7):520-31
pubmed: 16799471
Clin Cancer Res. 2017 Feb 1;23(3):707-716
pubmed: 27496866
Annu Rev Immunol. 2019 Apr 26;37:269-293
pubmed: 30649988
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32785653
Nat Rev Immunol. 2011 Oct 25;11(11):750-61
pubmed: 22025054
Nat Immunol. 2016 Aug 19;17(9):1025-36
pubmed: 27540992
Haematologica. 2015 Apr;100(4):489-98
pubmed: 25596273
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32005-32016
pubmed: 33229588
J Immunol. 2014 Feb 1;192(3):1241-8
pubmed: 24395917
J Invest Dermatol. 2017 Jul;137(7):1493-1500
pubmed: 28344062
Nat Immunol. 2019 Aug;20(8):1012-1022
pubmed: 31263276
Cancer Immunol Res. 2017 Dec;5(12):1098-1108
pubmed: 29070650
Blood. 2005 Jul 15;106(2):609-16
pubmed: 15802534
Front Immunol. 2021 Feb 12;12:638841
pubmed: 33679798
Innate Immun. 2013 Feb;19(1):76-85
pubmed: 22781631
Nat Commun. 2020 Nov 25;11(1):5992
pubmed: 33239635
Immunity. 2017 Aug 15;47(2):323-338.e6
pubmed: 28813661
Front Immunol. 2021 Feb 03;11:621254
pubmed: 33613552
Cancer Res. 2013 Aug 1;73(15):4653-62
pubmed: 23761327
Cancer Lett. 2008 Aug 28;267(2):226-44
pubmed: 18579287
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Blood. 2002 May 15;99(10):3661-7
pubmed: 11986221
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6202-E6211
pubmed: 28696300
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
Nat Commun. 2016 Aug 19;7:12528
pubmed: 27538380
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
Immunol Lett. 2016 May;173:26-35
pubmed: 26987844
Nat Med. 1999 Apr;5(4):405-11
pubmed: 10202929
Immunity. 2015 Jun 16;42(6):1130-42
pubmed: 26070484
Eur J Immunol. 2014 Oct;44(10):2903-17
pubmed: 25056715
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
J Immunol. 2005 Jan 15;174(2):727-34
pubmed: 15634892
Int Immunol. 2001 Apr;13(4):459-63
pubmed: 11282985
Cancer Immunol Res. 2017 Mar;5(3):248-256
pubmed: 28148545
Immunohorizons. 2017 May 1;1(3):10-19
pubmed: 28815225
J Immunol. 2004 May 1;172(9):5363-70
pubmed: 15100276
Front Immunol. 2018 Nov 27;9:2775
pubmed: 30542351
Arch Surg. 1987 Nov;122(11):1264-8
pubmed: 3675190
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33472858
Blood. 2006 Mar 1;107(5):2030-6
pubmed: 16304049
Nat Immunol. 2012 Sep;13(9):888-99
pubmed: 22797772
J Immunol. 1993 Jul 1;151(1):60-70
pubmed: 8326140
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21659-64
pubmed: 21118979
Cell. 2020 Apr 16;181(2):442-459.e29
pubmed: 32302573
J Immunol. 2003 Feb 1;170(3):1249-56
pubmed: 12538683
Elife. 2017 Dec 29;6:
pubmed: 29286001
Hepatology. 2013 Mar;57(3):1107-16
pubmed: 23225218
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
Immunity. 1996 Jun;4(6):573-81
pubmed: 8673704
Front Immunol. 2021 Jan 25;11:586126
pubmed: 33569050
J Immunol. 2014 Apr 15;192(8):3805-15
pubmed: 24646734
J Exp Med. 2002 Feb 4;195(3):343-51
pubmed: 11828009
PLoS One. 2012;7(5):e36928
pubmed: 22629344
Cancer. 2008 Feb 15;112(4):863-75
pubmed: 18203207
J Immunol. 2015 Sep 15;195(6):2818-28
pubmed: 26276870
Mol Cells. 2013 Nov;36(5):432-8
pubmed: 24158612
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486257
Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1313-9
pubmed: 23520167
Clin Cancer Res. 2020 Jun 15;26(12):2827-2837
pubmed: 32376655
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Blood. 2005 Jan 15;105(2):721-7
pubmed: 15367431
J Immunol. 2018 Sep 1;201(5):1478-1490
pubmed: 30061197
Cell Rep. 2016 Nov 22;17(9):2445-2459
pubmed: 27840052
Immunity. 2021 Aug 10;54(8):1883-1900.e5
pubmed: 34331874
Cytokine Growth Factor Rev. 2015 Dec;26(6):647-57
pubmed: 26115564
Cancer. 1996 Apr 1;77(7):1226-43
pubmed: 8608497
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Nat Rev Immunol. 2009 Aug;9(8):568-80
pubmed: 19629084
FASEB J. 2018 Oct;32(10):5365-5377
pubmed: 29763380
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Trends Immunol. 2020 Dec;41(12):1062-1071
pubmed: 33250080
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Immunol Rev. 2017 Mar;276(1):112-120
pubmed: 28258695
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Front Immunol. 2016 Oct 06;7:402
pubmed: 27766097
J Immunol. 2003 Sep 1;171(5):2366-73
pubmed: 12928383
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Eur J Immunol. 2014 Jun;44(6):1814-22
pubmed: 24510590
Sci Signal. 2019 Aug 27;12(596):
pubmed: 31455725
J Exp Med. 2015 Sep 21;212(10):1497-512
pubmed: 26347472